A Phase 3 interventional study of Ziltivekimab and Placebo in Cardiovascular Risk and Acute Myocardial Infarction (AMI), sponsored by Novo Nordisk A/S. Active, not recruiting at 836 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 440 studies in Myocardial Infarction with a site in United States — 41 open to participants now, 65 under way, 9 of them phase 3. Myocardial Infarction · United States.
Among the 440 studies in Myocardial Infarction with a site in United States, this one is the 20th largest by planned enrollment of the 301 interventional ones that give a count, is one of 15 that started in 2024, is one of 67 in phase 3, reaches primary completion later than 24 of the 64 other live ones, and was the 406th registered.
2,274 studies on the registry are indexed under Myocardial Infarction; 375 are open to participants now.
Browse Myocardial Infarction studies →41 of the 440 studies in Myocardial Infarction with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Verve Therapeutics, Inc. · Sites in United States
Ages 18–70
Columbia University · Sites in United States
Ages 18+
Amgen · Sites in United States, Australia, Canada and 1 more country
Ages 50–105
Abcentra · Sites in United States, Czechia, Hungary and 6 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
440 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 61 · Phase 3 76 · Phase 4 25
First in 1988; this study’s year is marked. 15 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 160 across the 301 interventional studies, 514 across the 136 observational. Of the 337 that completed or were terminated, 132 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
143 of 440 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Novo Nordisk A/S has 3 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
18 of the studies in Myocardial Infarction with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT05371470Mayo ClinicVoice Analysis Technology to Detect and Manage Depression and Anxiety in Cardiac Rehabilitation | 2026-11 |
| NCT04973397Centre hospitalier de l'Université de Montréal (CHUM)Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study | 2026-12 |
| NCT04521699Mayo ClinicExamination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk. | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 440 studies in Myocardial Infarction with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). Which treatment participants get is decided by chance. The chance of getting ziltivekimab or placebo is the same. The participant will need to inject the study medicine into a flat skin surface in there stomach, thigh, or upper arm once every month. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study will last for about 2 years.
Key inclusion:
ST-segment elevation myocardial infarction (STEMI) with all the following: a) Relevant onset of symptoms suggestive of cardiac ischaemia within 12 hours before hospitalisation, at the investigator's discretion.
b) (ECG)-changes (in the absence of left ventricular hypertrophy or left bundle branch block): ST-segment elevation at the J point in at least two contiguous leads greater than or equal 0.25 (millivolt) mV in men less than 40 years, greater than or equal 0.2 mV in men greater than or equal 40 years, or greater than or equal 0.15 mV in women in leads V2-V3; and/or greater than or equal 0.1 mV in all other leads.
OR
Key exclusion:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive an initial loading dose of ziltivekimab Dose 1 subcutaneously (s.c.) as early as possible after invasive procedure, and latest within 36 hours of hospitalisation for ST-elevation myocardial infarction (STEMI) and within 48 hours of hospitalisation for non-ST-elevation myocardial infarction (NSTEMI), followed by ziltivekimab Dose 2 s.c. once-monthly during the treatment period (estimated up to 2 years) added to standard of care.
Drug: Ziltivekimab
Participants will receive placebo matched to ziltivekimab at an initial loading dose subcutaneously (s.c.) as early as possible after invasive procedure, and latest within 36 hours of hospitalisation for STEMI and latest within 48 hours of hospitalisation for NSTEMI, followed by placebo matched to ziltivekimab s.c. once-monthly during the treatment period (estimated up to 2 years) added to standard of care.
Drug: Placebo
Ziltivekimab will be adminsitered subcutaneously as an initial loading dose of Dose 1 followed by a maintenance dose of Dose 2 once- monthly.
Placebo matched to ziltivekimab will be adminsitered subcutaneously as an initial loading dose followed by a maintenance dose once-monthly.
Time to first occurrence of a 3-component major adverse cardiovascular event (MACE) endpoint comprising: Cardiovascular (CV) death, Non-fatal myocardial infarction (MI), Non-fatal stroke
Measured in months.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Number of CV death, non-fatal MI, non-fatal stroke
Measured as count of events.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Time to first occurrence of a composite MACE endpoint consisting of: All-cause mortality, Non-fatal MI, Non-fatal stroke
Measured in months.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Number of all-cause mortality, non-fatal MI, non-fatal stroke
Measured as count of events.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Time to first occurrence of non-fatal MI
Measured in months.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Time to first occurrence of MI (fatal and non-fatal)
Measured in months.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Time to first occurrence of non-fatal stroke
Measured in months.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Time to first occurrence of stroke (fatal and non-fatal)
Measured in months.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Time to first occurrence of a 3-component coronary MACE endpoint comprising:CV death, Non-fatal MI, Ischaemia-driven coronary revascularisation
Measured in months.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Time to first occurrence of a 5-component expanded MACE endpoint comprising: CV death, Non-fatal MI, Non-fatal stroke, Ischaemia-driven coronary revascularisation, Heart failure (HF) hospitalisation or urgent HF visit
Measured in months.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Number of CV death, non-fatal MI, non-fatal stroke, ischaemia-driven coronary revascularisation, or HF hospitalisation or urgent HF visit
Measired as count of events.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Time to first occurrence of a 3-component HF endpoint comprising: CV death, HF hospitalisation or urgent HF visit, Outpatient HF visit
Measured in months.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Number of CV deaths, HF hospitalisation or urgent HF visits or outpatient HF visit
Measured in count of events.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Time to first occurrence of a 2-component HF endpoint comprising: CV death, HF hospitalisation or urgent HF visit
Measured as months.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Number of CV deaths, HF hospitalisation or urgent HF visits
Measured in count of events.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Time to first occurrence of a 2-component expanded HF endpoint comprising: HF hospitalisation or urgent HF visit, Outpatient HF visit
Measured as months.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Number of HF hospitalisation or urgent HF visit or outpatient HF visit
Measured as count of events.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Number of outpatient HF visit
Measured in count of events.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Time to occurrence of CV death
Measured as months.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Time to occurrence of all-cause death
Measured as months.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Time to first occurrence of 6-component vascular event endpoint: CV death, Non-fatal MI, Non-fatal stroke, Ischaemia-driven coronary revascularisation, Non-coronary revascularisation procedure, Any other non-coronary ischaemic event excluding stroke
Measured in months.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Number of CV death, non-fatal MI and non-fatal stroke, ischaemia-driven coronary revascularisation, non-coronary revascularisation procedure, or any other non-coronary ischaemic event excluding stroke
Measured as count of events.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Number of ischaemia-driven coronary revascularisation
Measured as count of events.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Time to first occurrence of ischaemia-driven coronary revascularisation or any non-coronary revascularisation
Measured in months.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Number of ischaemia-driven coronary revascularisation or any non-coronary revascularisation
Measured as count of events.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Number of cardiovascular hospitalisations
Measured as count of events.
Time frame: From randomisation (month 0) to 1 month/ 30 days
Number of cardiovascular hospitalisations
Measured as count of events.
Time frame: From randomisation (month 0) to 12 months
Number of hospitalisations with infection as primary cause or death due to infection
Measured as count of events.
Time frame: From randomisation (month 0) to end-of-study (up to 25 months)
Change in high-sensitivity C-reactive protein (hs-CRP)
Measured as ratio to baseline.
Time frame: From randomisation (month 0) to 6 months
Showing the first 100 of 836 sites across 24 countries. Choose a country and city above to see the rest.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Jan 2027, 31 months after the start.
Of 57 phase 3 interventional studies under Myocardial Infarction, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 77. This study's planned 31 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ziltivekimab